| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.6 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.6 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |